Shuttle Pharmaceuticals Holdings, Inc. Overview
Pro stress-test →Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) owns a pharmaceutical software AI-driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore chemical space more efficiently and make informed decisions during early-stage drug development.
Strategic Profile
Pro stress-test →As a discovery and development stage specialty pharmaceutical company, Shuttle is focused on improving outcomes for cancer patients treated with radiation therapy. The company has been awarded patents for its radiation sensitizing HDAC inhibitor technology platform, which reduces side effects for cancer patients treated with radiation therapy.
Competitive Landscape
Pro stress-test →Shuttle competes in the specialized oncology drug discovery and AI-enabled molecular discovery space. Key competitive areas include established radiation oncology pharma companies (Merck, Bayer), AI-native drug discovery platforms (Exscientia, Atomwise, DeepMind Pharma), and large pharma's internal HDAC inhibitor programs. Shuttle's differentiated positioning lies in its focused application of AI to radiation sensitization, a narrower niche than broader oncology or AI discovery competitors.
Industry Context
Shuttle Pharmaceuticals Holdings, Inc. operates in AI-enabled oncology drug discovery.
Key facts
Founded: 2012 · Headquarters: Gaithersburg, Maryland · Revenue: $0 · Market cap: N/A